4D Molecular Therapeutics Inc.
Last updated September 27, 2026
Organization details
- Legal name
- 4D Molecular Therapeutics Inc.
- Ownership
- Public
- Status
- Active
- SIC code
- 2836 — Biological Products, (No Diagnostic Substances)
- Jurisdiction of incorporation
- Delaware
- Headquarters city
- Emeryville
- Headquarters state / province
- California
- Headquarters country
- United States
- Fiscal year end
- December
- Ticker symbol
- FDMT
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001650648
- EIN
- 47-3506994
Board of directors
-
Charles Theuer · DirectorSince 2023
-
David Kirn · Director · See RemarksSince 2023
-
Glenn Sblendorio · DirectorSince 2026
-
Jacob Chacko · DirectorSince 2023
-
John F. Milligan · DirectorSince 2023
-
Nancy Miller-Rich · DirectorSince 2023
-
Noriyuki Kasahara · DirectorSince 2023
-
Shawn Tomasello · DirectorSince 2023
-
Susannah Gray · DirectorSince 2023
Chief executives
David Kirn
· Chief Executive Officer
Dates unknown
Director election results
Annual meeting of June 17, 2026. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
82.3%
-
96.5%
-
96.8%
Board connections
6 of this board's directors also sit on 9 other boards.
- via Nancy Miller-Rich
- via Susannah Gray
- via Shawn Tomasello
- via John F. Milligan
- via Shawn Tomasello
- via Susannah Gray
- via Glenn Sblendorio
- via Jacob Chacko
- via John F. Milligan
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $0
- 0 purchases by 0 insiders
- Sold, last 12 months
- $4,651,074
- 25 sales by 3 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Sep 16, 2026 | Bizily Scott Officer (Chief Legal Officer) | Option exercise | +1,635 | $4.14 | $6,769 |
| Sep 16, 2026 | Bizily Scott Officer (Chief Legal Officer) | Open-market sale | −1,635 | $13.65 | $22,318 |
| Sep 14, 2026 | David Kirn Director, Officer (See Remarks) | Open-market sale | −58,333 | $13.90 | $811,004 |
| Sep 1, 2026 | Bizily Scott Officer (Chief Legal Officer) | Option exercise | +584 | $6.49 | $3,790 |
| Sep 1, 2026 | Bizily Scott Officer (Chief Legal Officer) | Open-market sale | −584 | $14.00 | $8,176 |
| Aug 19, 2026 | David Kirn Director, Officer (See Remarks) | Option exercise | +50,000 | $4.14 | $207,000 |
| Aug 19, 2026 | David Kirn Director, Officer (See Remarks) | Open-market sale | −43,149 | $15.36 | $662,622 |
| Aug 19, 2026 | David Kirn Director, Officer (See Remarks) | Open-market sale | −25,927 | $16.42 | $425,651 |
| Aug 17, 2026 | Bizily Scott Officer (Chief Legal Officer) | Option exercise | +1,635 | $4.14 | $6,769 |
| Aug 17, 2026 | Bizily Scott Officer (Chief Legal Officer) | Open-market sale | −1,635 | $12.20 | $19,947 |
| Aug 13, 2026 | Bizily Scott Officer (Chief Legal Officer) | Option exercise | +1,635 | $4.14 | $6,769 |
| Aug 13, 2026 | Bizily Scott Officer (Chief Legal Officer) | Open-market sale | −1,635 | $12.00 | $19,620 |
| Aug 4, 2026 | David Kirn Director, Officer (See Remarks) | Open-market sale | −26,842 | $10.23 | $274,596 |
| Aug 3, 2026 | David Kirn Director, Officer (See Remarks) | Open-market sale | −12,415 | $10.05 | $124,722 |
| Jul 10, 2026 | David Kirn Director, Officer (See Remarks) | Open-market sale | −15,283 | $12.01 | $183,560 |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.